Emerald Advisers Inc. PA Trims Position in bluebird bio, Inc. (BLUE)

Emerald Advisers Inc. PA lessened its position in shares of bluebird bio, Inc. (NASDAQ:BLUE) by 6.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 183,512 shares of the biotechnology company’s stock after selling 12,662 shares during the quarter. Emerald Advisers Inc. PA owned 0.40% of bluebird bio worth $25,205,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC increased its position in bluebird bio by 9.6% in the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock worth $705,301,000 after buying an additional 587,236 shares in the last quarter. Capital Research Global Investors grew its position in shares of bluebird bio by 9.9% during the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock worth $576,001,000 after purchasing an additional 493,072 shares in the last quarter. Baillie Gifford & Co. grew its position in shares of bluebird bio by 3.8% during the second quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock worth $567,339,000 after purchasing an additional 196,025 shares in the last quarter. Vanguard Group Inc. grew its position in shares of bluebird bio by 10.7% during the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock worth $373,884,000 after purchasing an additional 343,856 shares in the last quarter. Finally, BlackRock Inc. grew its position in shares of bluebird bio by 4.3% during the second quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock worth $348,801,000 after purchasing an additional 138,141 shares in the last quarter.

In other news, insider Jeffrey T. Walsh sold 1,250 shares of bluebird bio stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $95.41, for a total value of $119,262.50. Following the sale, the insider now directly owns 28,555 shares in the company, valued at $2,724,432.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sullivan sold 861 shares of bluebird bio stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $93.83, for a total transaction of $80,787.63. Following the completion of the sale, the insider now owns 5,924 shares in the company, valued at $555,848.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 150,002 shares of company stock worth $18,840,335. Insiders own 3.90% of the company’s stock.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The firm had revenue of $7.71 million for the quarter, compared to the consensus estimate of $8.47 million. During the same period in the previous year, the business earned ($2.07) EPS. The firm’s revenue was up 397.4% compared to the same quarter last year.

Several analysts recently issued reports on BLUE shares. Jefferies Group LLC reiterated a “buy” rating and set a $88.00 target price on shares of bluebird bio in a research report on Friday, August 11th. BMO Capital Markets reiterated a “buy” rating and set a $108.00 target price on shares of bluebird bio in a research report on Friday, August 4th. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $186.00 target price on shares of bluebird bio in a research report on Friday, October 6th. Maxim Group reiterated a “buy” rating and set a $170.00 target price (up previously from $100.00) on shares of bluebird bio in a research report on Monday, October 9th. Finally, BTIG Research raised bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 price target for the company in a research note on Thursday. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $128.70.

WARNING: “Emerald Advisers Inc. PA Trims Position in bluebird bio, Inc. (BLUE)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was stolen and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/02/emerald-advisers-inc-pa-trims-position-in-bluebird-bio-inc-blue.html.

bluebird bio Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

What are top analysts saying about bluebird bio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for bluebird bio Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit